

Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting

Bio-Medicine.Org

REDWOOD CITY, Calif., April 29, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced today that complete results from the Company's Phase 2b study of [PT003](#) [1] in patients with moderate-to-very severe COPD will be presented during a late-breaker poster session at the upcoming annual meeting of the American Thoracic Society (ATS). PT003 (GFF-MDI) is a proprietary, fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol, an established, long-acting beta-2 agonist (LABA) delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA MDI). It is the first and only dual long-acting rapid bronchodilator LAMA-LABA combination product in development in an HFA MDI formulation, the most widely used inhalation drug delivery format.

"Our presentation at this year's ATS represents a particularly important step in the progression of Pearl's bronchodilator franchise," said [Chuck Bramlage](#) [2], Pearl Therapeutics' chief executive officer. "Not only is it an opportunity to present our strong clinical evidence to peers, but from a business perspective, it speaks to the speed and fiscal efficiency with which Pearl has expedited the clinical development of our lead bronchodilator combination and its individual components. In fewer than four years since initial financing, Pearl has completed the significant Phase 2b study being highlighted at ATS, as well as other key clinical and non-clinical studies. This is a testimonial to the Pearl team and its novel co-suspension platform. We expect this momentum will continue as we advance PT003 and its components, into a series of four additional Phase 2b studies, and make plans for Phase 3 trials in parallel."

The ATS annual meeting is taking place May 13-18 in the Colorado Convention Center in Denver, CO. Information regarding the ATS presentations
'/>"/>

[SOURCE](#) [3]

Source URL (retrieved on 03/06/2015 - 3:39pm):

<http://www.mdtmag.com/news/2011/04/pearl-therapeutics-present-complete-pt003-results-phase-2b-copd-study-late-breaker-session-american-thoracic-society-annual-meeting>

Links:

Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD

Published on Medical Design Technology (<http://www.mdtmag.com>)

[1] <http://pearltherapeutics.com/PT003>

[2] <http://pearltherapeutics.com/management-team>

[3] <http://www.bio-medicine.org/medicine-technology-1/Pearl-Therapeutics-to-Present-Complete-PT003-Results-from-Phase-2b-COPD-Study-in-a-Late-Breaker-Session-at-the-American-Thoracic-Society-Annual-Meeting-16777-1/>